A randomized, single-blind, three-part, phase III trial to investigate RDX-022 for the treatment of hyperkalaemia

Trial Profile

A randomized, single-blind, three-part, phase III trial to investigate RDX-022 for the treatment of hyperkalaemia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Jan 2017

At a glance

  • Drugs RDX 7675 (Primary)
  • Indications Hyperkalaemia
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 03 Jan 2017 Status changed from planning to recruiting, as per an Ardelyx media release.
    • 09 May 2016 According to an Ardelyx media release, this trial is expected to initiate during the fourth quarter 2016.
    • 09 May 2016 Planned initiation date changed from 1 Jul 2016 to 1 Oct 2016, as per Ardelyx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top